StockNews.AISignal intelligence
Alnylam Pharmaceuticals, Inc. · NASDAQ · Healthcare
Browse public ALNY signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Biotech equities are rallying, with IBB up nearly 5% and at new all-time highs, signaling renewed demand for biotech names. While ALNY has no company-specific news in the piece, sector momentum could lift high-growth RNAi players and expand multiples near-term. Traders should monitor pipeline milestones and regulatory updates that could unlock value for ALNY.
View signal analysisAlnylam beat Q2 EPS estimates but missed revenue, trimming 2026 TTR sales guidance amid ATTR-CM market normalization. Amvuttra led product revenue; Onpattro contributions were modest, and nucrisiran progresses remain a key uncertainty. The stock fell to a 52-week low, signaling near-term downside unless trial data renews confidence.
View signal analysisAlnylam teams with Inceptive to fuse RNAi expertise with AI foundation models to accelerate therapeutic discovery. The partnership is valued up to $2 billion, with a $30 million upfront and Inceptive equity in play, plus milestone payments tied to preclinical, regulatory, and sales milestones. If successful, the collaboration could accelerate Alnylam's 2030 pipeline expansion and productivity.
View signal analysisAlnylam Pharmaceuticals' stock has historically faced an average drawdown of -25% during major market shocks. This information suggests that investors should be prepared for volatility and consider their long-term investment strategies accordingly.
View signal analysisAlnylam Pharmaceuticals has entered into a significant research collaboration with Tenaya Therapeutics, valued at up to $1.13 billion, focused on developing treatments for heart diseases. This partnership solidifies Alnylam's position in the cardiovascular field and could lead to potent revenue streams as the research progresses.
View signal analysisAlnylam Pharmaceuticals' 'Alnylam 2030' roadmap emphasizes leadership in TTR diseases and plans to reinvest revenues into R&D. The company projects significant revenue growth, forecasting combined net product revenues of $4.9 billion to $5.3 billion in 2026, despite recent share price declines of over 10%.
View signal analysis